ABSTRACT
The main objective of the present work was to develop sustained release matrix tablets of Atenolol. To reduce the frequency of administration and to improve the patient compliance, a once daily sustained release formulation of Atenolol is desirable. So sustained release Matrix Tablet of Atenolol was designed by using different polymers viz.Starch, Xanthan Gum, Vee Gum , Guar Gum, Gum Accacia, Tragacanth, Hupu Gum were used as natural polymers and Eudragit-L100, Ethyl Cellulose, Sodium Carboxy Methyl Cellulose (Na-CMC) ,Hydroxy Propyl Methyl Cellulose (HPMC) (5&15cps), Methyl Cellulose, Kollidon were used as synthetic polymers. After fixing the ratio of drug and polymer for control the release of drug up to desired time, the release rates were modulated by Single polymer, combination of two different rates controlling material. The FT-IR study revealed that there was no chemical interaction between drug and excipients. The granules were prepared by dry granulation method. Precompressional parameters i.e. angle of repose, percent compressibility, and Hausner’s ratios were studied. These results indicate that granules are good flowing characteristics. After evaluation of physical properties like Weight variation, Hardness, Thickness, Friability of tablet, the different formulations checked for the Percentage Drug content which having good uniformity. The results of drug dissolution studies showed improved drug release, retardation effects of the polymers and could achieve better performance. After eight hours dissolution test, dissolution profiles showed that better sustained release was observed from starch and veegum containing formulation and eudragit and ethyl cellulose containing formulation of atenolol matrix tablet. It was also observed that the presence of starch caused an increase in the release rate of atenolol matrix tablet. The present study shows a relatively simple method to design and develop Atenolol matrix tablet.
ABSTRACT
Diabetes mellitus is a chronic ailment that impairs the production of or response to insulin, a hormone that helps to convert food into energy. Its complications are responsible for excess morbidity and mortality, loss of independence and reduce quality of life. Among the major cause of disablement and early death are ischemic heart disease, retinopathy, nephropathy, peripheral vascular disease and neuropathy. Insulin replacement therapy has been used in the clinical management of diabetes mellitus for more than 85 years. As subcutaneous injection is a painful episode so various approaches like transdermal, pulmonary, intranasal, colon targeted delivery, oral delivery is tried as an alternative way. Among them oral delivery is the challenging one because insulin cannot administered orally due to rapid enzymatic digestion in stomach. For oral delivery various technology, formulation and various modification approaches are going on. It is high time to invent an acceptable non-invasive insulin delivery for the diabetes to improve patient compliance and decrease the morbidity.
ABSTRACT
Diabetes mellitus is a chronic ailment that impairs the production of or response to insulin, a hormone that helps to convert food into energy. Its complications are responsible for excess morbidity and mortality, loss of independence and reduce quality of life. Among the major cause of disablement and early death are ischemic heart disease, retinopathy, nephropathy, peripheral vascular disease and neuropathy. Insulin replacement therapy has been used in the clinical management of diabetes mellitus for more than 85 years. As subcutaneous injection is a painful episode so various approaches like transdermal, pulmonary, intranasal, colon targeted delivery, oral delivery is tried as an alternative way. Among them oral delivery is the challenging one because insulin cannot administered orally due to rapid enzymatic digestion in stomach. For oral delivery various technology, formulation and various modification approaches are going on. It is high time to invent an acceptable non-invasive insulin delivery for the diabetes to improve patient compliance and decrease the morbidity.
ABSTRACT
A new, simple, specific, sensitive, rapid and economical procedure has been developed for determination of Nitroglycerin in its dosage form. The objective of this validation of an analytical procedure is to demonstrate that the drug Nitroglycerin is suitable for its intended purpose. The analytical method development recommends the quality, purity and specificity of the drug Nitroglycerin tablet form during the manufacturing process and hence the standard of the drug may not vary, which produce the desirable therapeutic effect. The method is based on the ultraviolet absorbance maxima of the above drug at 210nm. The drug obeyed Beer's law in the concentration range of 15μg/ml in methanol. The proposed methods were successfully applied for the determination of drug in commercial tablet preparations. The results of the analysis have been validated statistically and by recovery studies.